Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised Eyepoint Pharmaceuticals’ price target to $55 from $47 and maintained an “overweight” rating, implying nearly 349% upside from the previous close.
• Analyst sentiment is broadly positive, with an average “Moderate Buy” rating and a $44.38 consensus target, although ratings range from “Strong Buy” to “Sell.”
• Eyepoint reported a quarterly EPS loss of $1.09, missing estimates by $0.09, while revenue of $0.51 million exceeded expectations; institutional investors own 99.41% of the stock.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) had its price target hoisted by equities researchers at Cantor Fitzgerald from $47.00 to $55.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Cantor Fitzgerald's price target indicates a potential upside of 348.98% from the company's previous close.

EYPT has been the subject of several other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a "buy" rating and a $40.00 price objective for the company. Royal Bank Of Canada decreased their price target on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Guggenheim reissued a "buy" rating and set a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Finally, Chardan Capital boosted their target price on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $44.38.

Eyepoint Pharmaceuticals Trading Up 5.0%

Shares of EYPT opened at $12.25 on Thursday. The business's 50-day moving average price is $13.12 and its 200 day moving average price is $13.79. The stock has a market capitalization of $1.03 billion, a P/E ratio of -3.50 and a beta of 1.76. Eyepoint Pharmaceuticals has a 1-year low of $9.51 and a 1-year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.39 million. On average, research analysts predict that Eyepoint Pharmaceuticals will post -3.3 earnings per share for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Large investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock valued at $85,000 after buying an additional 794 shares during the last quarter. RWC Asset Management LLP grew its position in shares of Eyepoint Pharmaceuticals by 6.4% in the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company's stock valued at $315,000 after acquiring an additional 1,040 shares during the period. MCF Advisors LLC increased its stake in shares of Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company's stock worth $273,000 after purchasing an additional 1,149 shares during the last quarter. Raymond James Financial Inc. raised its holdings in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock valued at $112,000 after purchasing an additional 1,177 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company's stock valued at $74,000 after purchasing an additional 1,358 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source